CN112135830B - 氧代取代化合物 - Google Patents

氧代取代化合物 Download PDF

Info

Publication number
CN112135830B
CN112135830B CN201980028757.2A CN201980028757A CN112135830B CN 112135830 B CN112135830 B CN 112135830B CN 201980028757 A CN201980028757 A CN 201980028757A CN 112135830 B CN112135830 B CN 112135830B
Authority
CN
China
Prior art keywords
oxy
azetidin
carboxylic acid
chemical
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980028757.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN112135830A (zh
Inventor
金井利夫
小池祥子
深谷孝幸
上杉惇一郎
水嶋真吾
须田仁志
水上雄贵
井熊洋平
砂塚敏明
野口吉彦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Pharmaceuticals Co Ltd
Kitasato Institute
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68295570&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN112135830(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sumitomo Pharmaceuticals Co Ltd, Kitasato Institute, Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Pharmaceuticals Co Ltd
Priority to CN202410723545.9A priority Critical patent/CN118638140A/zh
Publication of CN112135830A publication Critical patent/CN112135830A/zh
Application granted granted Critical
Publication of CN112135830B publication Critical patent/CN112135830B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)
CN201980028757.2A 2018-04-27 2019-04-26 氧代取代化合物 Active CN112135830B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410723545.9A CN118638140A (zh) 2018-04-27 2019-04-26 氧代取代化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018-087761 2018-04-27
JP2018087761 2018-04-27
PCT/JP2019/018011 WO2019208797A1 (ja) 2018-04-27 2019-04-26 オキソ置換化合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410723545.9A Division CN118638140A (zh) 2018-04-27 2019-04-26 氧代取代化合物

Publications (2)

Publication Number Publication Date
CN112135830A CN112135830A (zh) 2020-12-25
CN112135830B true CN112135830B (zh) 2024-06-14

Family

ID=68295570

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980028757.2A Active CN112135830B (zh) 2018-04-27 2019-04-26 氧代取代化合物
CN202410723545.9A Pending CN118638140A (zh) 2018-04-27 2019-04-26 氧代取代化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410723545.9A Pending CN118638140A (zh) 2018-04-27 2019-04-26 氧代取代化合物

Country Status (15)

Country Link
US (3) US11702431B2 (https=)
EP (1) EP3786168A4 (https=)
JP (2) JP7360132B2 (https=)
KR (1) KR102679411B1 (https=)
CN (2) CN112135830B (https=)
AU (1) AU2019259818B2 (https=)
CA (1) CA3098433A1 (https=)
EA (1) EA202092579A1 (https=)
IL (1) IL278262B2 (https=)
MX (1) MX2020011367A (https=)
PH (1) PH12020551772A1 (https=)
SG (1) SG11202010661SA (https=)
TW (1) TWI829686B (https=)
UA (1) UA129150C2 (https=)
WO (1) WO2019208797A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2020138499A1 (ja) * 2018-12-28 2021-11-04 大日本住友製薬株式会社 アルキル置換化合物
EP4049680A4 (en) * 2019-10-25 2024-01-10 Sumitomo Pharma Co., Ltd. NEW SUBSTITUTED CONDENSED RING CONNECTION
US11476003B2 (en) * 2020-12-15 2022-10-18 Biodesix, Inc. Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitalization, from clinical characteristics and basic laboratory findings
WO2024128238A1 (ja) 2022-12-13 2024-06-20 住友ファーマ株式会社 細菌感染症の治療剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459096A (zh) * 2014-05-19 2017-02-22 莱姆派克斯制药公司 硼酸衍生物及其治疗用途
US20170073360A1 (en) * 2015-09-11 2017-03-16 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2705393A1 (en) 2007-11-13 2009-05-22 Protez Pharmaceuticals, Inc. Beta-lactamase inhibitors
AU2013355110B2 (en) 2012-12-07 2017-11-09 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
MX2015008627A (es) 2013-01-04 2015-09-23 Rempex Pharmaceuticals Inc Derivados de acido boronico y usos terapeuticos de los mismos.
KR20150103269A (ko) 2013-01-04 2015-09-09 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
EP2943204B1 (en) 2013-01-10 2019-03-13 Venatorx Pharmaceuticals Inc Beta-lactamase inhibitors
EP2970340B1 (en) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2015191907A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2016003929A1 (en) 2014-07-01 2016-01-07 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459096A (zh) * 2014-05-19 2017-02-22 莱姆派克斯制药公司 硼酸衍生物及其治疗用途
US20170073360A1 (en) * 2015-09-11 2017-03-16 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors

Also Published As

Publication number Publication date
US20210147448A1 (en) 2021-05-20
PH12020551772A1 (en) 2021-07-12
TW201945006A (zh) 2019-12-01
KR102679411B1 (ko) 2024-07-01
TWI829686B (zh) 2024-01-21
IL278262B1 (en) 2024-12-01
KR20210005910A (ko) 2021-01-15
IL278262B2 (en) 2025-04-01
JPWO2019208797A1 (ja) 2021-05-27
EP3786168A1 (en) 2021-03-03
MX2020011367A (es) 2021-02-09
TW202421162A (zh) 2024-06-01
US20230287009A1 (en) 2023-09-14
AU2019259818A1 (en) 2020-11-26
IL278262A (en) 2020-12-31
JP7360132B2 (ja) 2023-10-12
EA202092579A1 (ru) 2021-04-01
JP2023168413A (ja) 2023-11-24
SG11202010661SA (en) 2020-11-27
AU2019259818B2 (en) 2023-06-01
CA3098433A1 (en) 2019-10-31
CN112135830A (zh) 2020-12-25
US11702431B2 (en) 2023-07-18
BR112020021631A8 (pt) 2023-02-28
US11066425B1 (en) 2021-07-20
BR112020021631A2 (pt) 2021-01-26
JP7598594B2 (ja) 2024-12-12
EP3786168A4 (en) 2022-03-23
WO2019208797A1 (ja) 2019-10-31
CN118638140A (zh) 2024-09-13
UA129150C2 (uk) 2025-01-29

Similar Documents

Publication Publication Date Title
US20250206761A1 (en) Haloindole macrocyclic compounds for the treatment of cancer
JP7598594B2 (ja) オキソ置換化合物
TWI773687B (zh) β內醯胺酶抑制劑化合物
TWI597281B (zh) β－內醯胺酶抑制劑化合物
WO2019009369A1 (ja) イミン誘導体
WO2019009370A1 (ja) アミド誘導体
JP7654554B2 (ja) 新規置換縮環型化合物
JP7550421B2 (ja) オキソ置換化合物からなる医薬
HK40043668A (en) Oxo-substituted compound
TWI915735B (zh) 氧基取代化合物
HK40111382A (zh) 氧代取代化合物
BR112020021631B1 (pt) Composto oxo-substituído, agente de inibição de b-lactamase, composição farmacêutica, medicamento e usos
HK40043668B (zh) 氧代取代化合物
EA048506B1 (ru) Оксо-замещенное соединение
WO2020138499A1 (ja) アルキル置換化合物
HK40072736A (en) Novel substituted condensed ring compound
JP2020105148A (ja) 非アリールヘテロ環置換芳香族化合物
HK40011101A (en) Beta-lactamase inhibitor compounds
HK40011101B (en) Beta-lactamase inhibitor compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40043668

Country of ref document: HK

CB02 Change of applicant information
CB02 Change of applicant information

Address after: Osaka City, Osaka of Japan

Applicant after: SUMITOMO PHARMACEUTICALS CO.,LTD.

Applicant after: THE KITASATO INSTITUTE

Address before: Osaka City, Osaka of Japan

Applicant before: Dainippon Sumitomo Pharma Co.,Ltd.

Applicant before: THE KITASATO INSTITUTE

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20260304

Address after: Osaka City, Osaka of Japan

Patentee after: SUMITOMO PHARMACEUTICALS CO.,LTD.

Country or region after: Japan

Address before: Osaka City, Osaka of Japan

Patentee before: SUMITOMO PHARMACEUTICALS CO.,LTD.

Country or region before: Japan

Patentee before: THE KITASATO INSTITUTE